Compare Stocks → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ANGNNASDAQ:GMTXNASDAQ:TERNNASDAQ:TH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANGNAngion Biomedica$6.48$0.46▼$2.04$30.11M0.686,718 shs224,800 shsGMTXGemini Therapeutics$27.55+3.9%$51.39$1.16▼$14.10$1.19B-0.12189,291 shs368,874 shsTERNTerns Pharmaceuticals$4.91+5.8%$6.39$3.26▼$13.51$317.43M-0.63853,115 shs495,921 shsTHTarget Hospitality$11.12+0.4%$9.97$8.49▼$16.80$1.12B2.09568,925 shs543,345 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANGNAngion Biomedica0.00%0.00%0.00%0.00%-86.67%GMTXGemini Therapeutics-1.78%-11.66%-56.02%-58.10%-11.75%TERNTerns Pharmaceuticals-2.32%+1.09%-24.68%-13.27%-63.44%THTarget Hospitality+0.64%+1.84%+1.56%+16.26%-10.28%Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANGNAngion BiomedicaN/AN/AN/AN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATERNTerns Pharmaceuticals4.1111 of 5 stars3.42.00.04.13.33.30.0THTarget Hospitality2.1634 of 5 stars1.35.00.00.02.71.72.5Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANGNAngion BiomedicaN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/ATERNTerns Pharmaceuticals2.75Moderate Buy$14.94204.23% UpsideTHTarget Hospitality2.50Moderate Buy$11.00-1.08% DownsideCurrent Analyst RatingsLatest TH, ANGN, GMTX, and TERN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024THTarget HospitalityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$13.00 ➝ $12.003/27/2024TERNTerns PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $18.003/26/2024THTarget HospitalityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.003/25/2024THTarget HospitalityOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$12.00 ➝ $10.003/18/2024TERNTerns PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.003/15/2024TERNTerns PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$5.503/15/2024TERNTerns PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$18.00 ➝ $19.003/14/2024THTarget HospitalityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $13.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANGNAngion Biomedica$2.30M0.00N/AN/A$1.32 per share0.00GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ATERNTerns Pharmaceuticals$1M317.43N/AN/A$4.13 per share1.19THTarget Hospitality$563.61M1.98$2.52 per share4.41$3.71 per share3.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANGNAngion Biomedica-$38.81MN/A0.00N/AN/AN/A-47.53%-40.55%N/AGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/ATERNTerns Pharmaceuticals-$90.21M-$1.27N/AN/AN/AN/A-33.55%-31.90%5/20/2024 (Estimated)THTarget Hospitality$173.70M$1.547.2216.121.1529.53%53.91%24.85%5/14/2024 (Estimated)Latest TH, ANGN, GMTX, and TERN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023TERNTerns Pharmaceuticals-$0.29-$0.29N/A-$0.29N/AN/A3/13/2024Q4 2023THTarget Hospitality$0.24$0.29+$0.05$0.29$118.00 million$126.20 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANGNAngion BiomedicaN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ATHTarget HospitalityN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANGNAngion BiomedicaN/A20.0020.00GMTXGemini TherapeuticsN/A71.4971.49TERNTerns PharmaceuticalsN/A22.3922.39THTarget Hospitality0.472.572.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANGNAngion Biomedica17.00%GMTXGemini Therapeutics75.42%TERNTerns Pharmaceuticals98.26%THTarget Hospitality32.40%Insider OwnershipCompanyInsider OwnershipANGNAngion Biomedica19.70%GMTXGemini Therapeutics12.90%TERNTerns Pharmaceuticals17.40%THTarget Hospitality68.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableANGNAngion Biomedica330.11 million24.18 millionNot OptionableGMTXGemini Therapeutics3143.33 million37.74 millionNot OptionableTERNTerns Pharmaceuticals6664.65 million53.40 millionNot OptionableTHTarget Hospitality984100.52 million31.97 millionNot OptionableTH, ANGN, GMTX, and TERN HeadlinesSourceHeadlineAnderson Valley’s Famous Pinot Noir Festival Celebrates Its 25th Yearforbes.com - April 26 at 5:19 PMKSA unleashes massive hospitality expansion – and a wealth of investment opportunitiesbreakingtravelnews.com - April 26 at 4:30 AMChatrium Grand Bangkok Wins Coveted LIV Hospitality Design Award for Stunning Designnewswit.com - April 25 at 11:30 PMBCCP highlights opportunities in travel industry in '4th Travel Talks'msn.com - April 23 at 9:25 PMAston Villa 3-1 AFC Bournemouthavfc.co.uk - April 23 at 9:25 PMJason P. Vlacich Implements A Sell Strategy: Offloads $582K In Target Hospitality Stockbenzinga.com - April 16 at 12:41 PM1,349,167 Shares in Target Hospitality Corp. (NASDAQ:TH) Bought by Voss Capital LLCmarketbeat.com - April 15 at 7:42 PMBournemouth vs Man Utd live: Score and latest updates from Vitality Stadiummsn.com - April 13 at 11:02 PMVanguard Group Inc. Acquires 523,398 Shares of Target Hospitality Corp. (NASDAQ:TH)marketbeat.com - April 13 at 4:31 AMTarget Hospitality Corp. (NASDAQ:TH) Short Interest Down 37.7% in Marchmarketbeat.com - April 12 at 3:16 PMHold Rating Maintained Amidst Acquisition Bid and Growth Prospects for Target Hospitalitymarkets.businessinsider.com - April 12 at 11:57 AMThe Analyst Landscape: 4 Takes On Target Hospitalitymarkets.businessinsider.com - April 12 at 11:57 AMDocuSign upgraded, Arista downgraded: Wall Street's top analyst callsfinance.yahoo.com - April 12 at 11:57 AMTarget Hospitality's (TH) "Hold" Rating Reiterated at Stifel Nicolausmarketbeat.com - April 12 at 8:23 AMTarget Hospitality Announces Partnership with Chard Métis Dene Groupfinance.yahoo.com - April 12 at 6:57 AMTarget Hospitality Announces Partnership with Chard Métis Dene Groupprnewswire.com - April 12 at 6:45 AMRosie Holidays opens new gallery to mark its 50th anniversaryfbcnews.com.fj - April 11 at 10:48 PMWall Street Favorites: 3 Under-$20 Stocks With Strong Buy Ratings for April 2024investorplace.com - April 11 at 1:46 PMTarget Hospitality Corp (TH)investing.com - April 11 at 12:47 PMKent Lake Capital LLC Lowers Position in Target Hospitality Corp. (NASDAQ:TH)marketbeat.com - April 6 at 7:36 PMWhy Target Hospitality Stock Surged Higher This Weekfool.com - March 28 at 1:31 PMTarget Hospitality Corp.cnn.com - March 27 at 10:24 AMTarget Hospitality's (TH) "Buy" Rating Reaffirmed at Stifel Nicolausmarketbeat.com - March 26 at 10:46 AMArrow offers to buy remaining stake Target Hospitalitymsn.com - March 25 at 7:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s Portfolio3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentAll Headlines Company DescriptionsAngion BiomedicaNASDAQ:ANGNAngion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.Gemini TherapeuticsNASDAQ:GMTXGemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Terns PharmaceuticalsNASDAQ:TERNTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.Target HospitalityNASDAQ:THTarget Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.